Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Chemicals
EPIC: TYR
Latest Price: 3.25p  (-7.14% Descending)
52-week High: 38.00p
52-week Low: 3.25p
Market Cap: 3.12M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
TyraTech Inc.
www.tyratech.com

TyraTech Nature's Technology effectively controls insects and parasites while providing a new level of safety for people, animals and the environment. TyraTech's patented scientific process targets receptors active only in invertebrates, not in humans or animals. TyraTech leverages this scientific platform to develop natural products that are as effective as traditional chemical options.

Full TyraTech Inc. profile here
Is TYR a Buy, Sell or Hold?Get your FREE analysis of TYR
Pdf

TyraTech hires US-based consultancy to seek partners for head lice product

25th Oct 2011, 8:58 am by Sergei Balashov TyraTech says its head lice product is effective at killing all stages of head lice, including several species that have become increasingly resistant to traditional synthetic treatments

TyraTech (LON:TYR) has hired US based consultancy Destum Partners to help it find global partners for its natural head lice product, looking to take advantage of an unmet need in the lucrative US market.

The environmentally friendly pesticides firm's head lice product represents its first entry into the personal health care market.

“We are very excited about entering the personal health care sector with what we believe will be the first of a number of products,” said executive chairman of TyraTech Alan Reade.

“This is a unique opportunity to deliver a highly effective and safe treatment for the currently unmet need of treating head lice which have proven to be resistant to traditional synthetic products.”

Between 6 million to 12 million head lice infestations occur in the US each year among children 3 to 11 years of age, with around 100 million infestations globally. In the US alone, expenses on treating head lice reach US$100 million, while the global market is estimated at US$300 million.

TyraTech noted increasing levels of resistance to standard synthetic pyrethroid treatments has become widespread and is well documented in the US, Europe and Israel.

Testing in independent laboratories has shown that TyraTech’s non-toxic formulation is highly effective at killing all stages of head lice, including several species that have become increasingly resistant to traditional synthetic treatments.

Market research has shown strong demand for an effective and safe naturally derived product, said Tyra.
“We look forward to working with our colleagues at Destum as we continue to move the development of our product forward,” said Reade.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.